Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma - Wikidata - awgldk - TriplyDB

Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma

Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma

http://www.wikidata.org/entity/Q33868732

about

Arginine deiminase expressed in vivo, driven by human telomerase reverse transcriptase promoter, displays high hepatoma targeting and oncolytic efficiency.Oncolytic adenovirus SG600-IL24 selectively kills hepatocellular carcinoma cell lines.

P2860

Q33914097-209179EE-BB72-461A-92CB-55693E5E6C28 Q34183175-E6B2E365-FF79-44C0-A97B-1E2AB3068E74

P2860

Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma

http://www.wikidata.org/entity/Q33868732

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@ast

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@en

type

label

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@ast

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@en

prefLabel

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@ast

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@en

P1433

Q33868732-F346439F-F93A-43EC-99E4-B855F50F3341

P1476

Q33868732-64419E71-0348-4A36-AB72-AE82A341F7FB

P2093

Q33868732-1929B12B-F31D-4C3D-A738-72B8121C0000

Q33868732-37F406D4-5794-4058-A018-BDA91FFCF508

Q33868732-68B5A1FE-B2BC-4576-AECB-07AB2AC71199

Q33868732-6FD61ADE-29D8-4009-9D21-6016BE28F106

Q33868732-743F5702-A03B-4E3B-857D-A64A945C65BC

Q33868732-8F2F201D-73EC-4F39-9B98-F44E03B4D600

Q33868732-A7ACC20C-BA3B-4EAA-BC2B-E4853E2C79D1

Q33868732-CEE48A55-37EB-43EA-BC6D-BE84C3560EFF

P2860

Q33868732-13298DA5-39DF-4EB1-87C2-FF0A32948701

Q33868732-22866F4E-D869-48F4-8F33-D299B4B5EA84

Q33868732-2A51DB74-3B3E-47FA-9172-2B5828608A4C

Q33868732-3A4DF11D-3736-4B03-AD4A-6E6E86A815D5

Q33868732-49BA2C38-BF6A-4C32-81D8-AF6F4977A098

Q33868732-4E4AC544-081F-4EC6-84BE-296C4E65EE1B

Q33868732-4E9F91F5-3E84-42C9-96AF-C0E6865D3E32

Q33868732-4FC4B2D3-1879-48F5-A392-EA45717D4905

Q33868732-57D042F4-AF4A-4E82-81E7-694C4A20E813

Q33868732-6BE8DB6D-E20C-4D79-9C53-47054B8DD841

P304

Q33868732-7BB30149-42F6-40B4-9CE3-D67CDE8558AB

P31

Q33868732-D7DFB357-AC15-4E1B-877A-8888770D3EC4

P356

Q33868732-0DB597A4-0507-4D12-BEAD-60485EBE706E

P407

Q33868732-B54DD417-C919-4799-973F-B790D114AF2A

P433

Q33868732-28F6F8DF-66CC-4EBA-A4DF-7A37C07485BE

P478

Q33868732-57B79D0D-A3C0-41CD-AAA2-75BCC5773266

P577

Q33868732-9697319B-7CFE-4974-A46D-D5E87A333E04

P5875

Q33868732-53A0BD47-B5F5-4264-A143-2621F0051FC2

P698

Q33868732-751F7BDD-E138-45A4-90B3-B5DA33EA8BCC

P921

Q33868732-A2EEF902-A4C6-4414-8971-EB7E77C33729

Q33868732-B64D671C-B24E-4965-AFE6-46E2F500E817

P932

Q33868732-EBDB5CBC-CB22-4219-A293-8749CA53A4EC

P356

WJG.V12.I47.7613

P1433

World Journal of Gastroenterology

P1476

Antitumor activity of an hTERT ...... human hepatocellular carcinoma

@en

P2093

Chang-Qing Su

http://www.w3.org/2001/XMLSchema#string

Jie Chen

http://www.w3.org/2001/XMLSchema#string

Lin-Fang Li

http://www.w3.org/2001/XMLSchema#string

Meng-Chao Wu

http://www.w3.org/2001/XMLSchema#string

Qi-Jun Qian

http://www.w3.org/2001/XMLSchema#string

Wei-Guo Wang

http://www.w3.org/2001/XMLSchema#string

Xing-Hua Wang

http://www.w3.org/2001/XMLSchema#string

Yong-Jing Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.

The development of conditionally replicative adenoviruses for cancer therapy.

ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.

Cancer burden in the year 2000. The global picture.

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

Cytolytic viruses as potential anti-cancer agents.

Replication-selective viruses for cancer therapy.

Progress and problems with the use of viral vectors for gene therapy.

Telomerase promoter-driven cancer gene therapy.

P304

7613-7620

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V12.I47.7613

http://www.w3.org/2001/XMLSchema#string

P407

P433

47

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

298736012

http://www.w3.org/2001/XMLSchema#string

P698

17171789

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4088042

http://www.w3.org/2001/XMLSchema#string